Latest News

AC Immune boldly prices Nasdaq IPO

AC Immune at the EPFL Innovation Park © AC Immune


14.09.2016 - The summer slump on the stock markets is over: AC Immune has confidently priced its long-awaited Nasdaq IPO. The Swiss Alzheimer’s specialist is expecting to raise up to US$68m (€60.5m) overseas.

AC Immune SA, which specialises in personalised treatment of neurodegenerative diseases, had announced their upcoming IPO in May. Now the Swiss drug maker has priced their shares. It will offer 4.5 million shares for between US$11 and US$13 each, bringing the total to US$54m. The company also intends to grant an optional 0.7 additional shares to cover over-allotments. All in all, AC Immune could raise US$68m in total.

The most advanced development project of AC Immune is the humanized monoclonal antibodies Crenezumab (RG7412), currently in Phase III. It is directed against the beta-amyloid plaques in the nerve cells of Alzheimer's patients and is designed to alleviate or help delay dementia symptoms. AC Immune, founded in 2003, will be listed on the New York Stock Exchange Nasdaq with the ticker symbol ACIU. 

AC Immune is not the only Swiss company to look for public money across the Atlantic. Late last week, Crispr Therapeutics filed to list on Nasdaq, NY, as well.

Cellectis and AstraZeneca in US$2.2bn deal

Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

Study: New breeding methods hardly contribute to climate protection

Up and down the country, national governments and the EU Commission (EC) are campaigning to facilitate the commercialisation of cis-gentic and...

Agomab Therapeutics NV raises US$100m in Series C financing

The closed financing round was led by Fidelity Management & Research Company. New investors EQT Life Sciences, Canaan and Dawn Biopharma/KKR, as...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics

Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Mithra raises €20m through private placement

Under the terms of the Private Placement, Armistice Capital committed to subscribe for 10 million new shares atz a share price of 2€ per share , of...

Scotland boosts bio-based manufacturing with £75m fund

Scottish Enterprise and Innovate UK will deliver the Launchpad programme, designed to focus on Scotland’s strengths in the sector. The packages,...

Majority of EU agri-council supports NGT deregulation

On the occasion of an informal meeting of EU agriculture ministers on NGT plant varieties (3.–5. September), a majority of ministers said they would...